ReviewCurrent opinion in nephrology and hypertension2014
Advanced glycation end product accumulation: a new enemy to target in chronic kidney disease?
Review in Current opinion in nephrology and hypertension, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 72 citations in OpenAlex.
- Trained Immunity as a Mechanistic Bridge Between Uremic Toxins, Atherosclerosis, and Vascular Calcification in Chronic Kidney Disease.Cardiovascular toxicology · 2026Review
- Effects of Ginkgo biloba extract on glycemic control, inflammatory markers, lipid profile, anthropometric indices, and safety parameters in patients with metabolic syndrome and type 2 diabetes: a meta-analysis.Diabetology & metabolic syndrome · 2026Review
- Next-generation therapeutics for diabetic kidney disease.Nature reviews. Nephrology · 2026Review
- Differential impact of advanced glycation end-products on cardiovascular risk across patient populations measured by skin autofluorescence: a meta-analysis.European journal of medical research · 2026Article
- Public Health Screening for Cardiometabolic Risk: Lessons from Advanced Glycation End-Products and ABC Target Achievement in Dalmatian Adults with Type 2 Diabetes.Biomedicines · 2025Article
- Serum Levels of NBiomedicines · 2025Article
- Relationships Between Insulin Resistance Surrogate Indicators and Chronic Kidney Disease in Non-Diabetic Individuals: A Retrospective Cross-Sectional Study.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025Article
- Protein glycation products associate with progression of kidney disease and incident cardiovascular events in individuals with type 1 diabetes.Cardiovascular diabetology · 2024Article
- Are There Differences in Skin Autofluorescence-Measured Advanced Glycation End-Product Levels between Chronic Kidney Disease and Kidney Transplant Recipients?Diagnostics (Basel, Switzerland) · 2024Article
- Matrisome Transcriptome Dynamics during Tissue Aging.Life (Basel, Switzerland) · 2024Article
- Recent Advances in the Management of Diabetic Kidney Disease: Slowing Progression.International journal of molecular sciences · 2024Review
- Amorphophallus campanulatus tuber extract protects diabetic nephropathy in streptozotocin-induced diabetic nephropathy rat model by regulating oxidative stress and TNF-α inflammatory pathway.Acta cirurgica brasileira · 2024Article
- A Review of Medicinal Plants with Renoprotective Activity in Diabetic Nephropathy Animal Models.Life (Basel, Switzerland) · 2023Review
- Skin Autofluorescence, a Noninvasive Biomarker of Advanced Glycation End-products, Is Associated With Frailty: The Rotterdam Study.The journals of gerontology. Series A, Biological sciences and medical sciences · 2022Article
- Review
- Role of Calcimimetics in Treating Bone and Mineral Disorders Related to Chronic Kidney Disease.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Mechanisms of Cardiorenal Protection With SGLT2 Inhibitors in Patients With T2DM Based on Network Pharmacology.Frontiers in cardiovascular medicine · 2022Article
- Glyoxal-Lysine Dimer, an Advanced Glycation End Product, Induces Oxidative Damage and Inflammatory Response by Interacting with RAGE.Antioxidants (Basel, Switzerland) · 2021Article
- PAR2-Induced Tissue Factor Synthesis by Primary Cultures of Human Kidney Tubular Epithelial Cells Is Modified by Glucose Availability.International journal of molecular sciences · 2021Article
- The AGE receptor, OST48 drives podocyte foot process effacement and basement membrane expansion (alters structural composition).Endocrinology, diabetes & metabolism · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
purpose of reviewThe critical role of advanced glycation end products (AGEs) in the progression of chronic diseases and their complications has recently become more apparent. This review summarizes the recent contributions to the field of AGEs in chronic kidney disease (CKD). RECENT
findingsOver the past 3 decades, AGEs have been implicated in the progression of CKD, and specifically diabetic nephropathy. Although numerous in-vitro and in-vivo studies highlight the detrimental role of AGEs accumulation in tissue injury, few prospective human studies or clinical trials show that inhibiting this process ameliorates disease. Nonetheless, recent studies have focused on the novel mechanisms that contribute to end-organ injury as a result of AGEs accumulation, as well as novel targets of therapy in kidney disease. SUMMARY: As the prevalence and the incidence of CKD rises in the United States, it is essential to identify therapeutic strategies that either delay the progression of CKD or improve mortality in this population. The focus of this review is on highlighting the recent studies that advance our current understanding of the mechanisms mediating AGEs-induced CKD progression, as well as novel treatment strategies that have the potential to abrogate this disease process. VIDEO ABSTRACT: http://links.lww.com/CONH/A12.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.